BuybackJun 9, 2026, 04:57 PM
Lakefront Biotherapeutics Launches 50M Stock Repurchase Program
AI Summary
Lakefront Biotherapeutics NV announced the initiation of a share repurchase program, allowing the company to repurchase ordinary shares for an aggregate amount of up to 50 million euros. Repurchases may be made no later than December 31, 2026. This program stems from an opportunity gained through a transaction with Gilead announced in March 2026, which permitted repurchases of up to $150 million. The primary objective of the program is to deliver shareholder value, with all purchased shares to be held as treasury shares.
Key Highlights
- Lakefront Biotherapeutics launched a share repurchase program for up to 50 million euros.
- Repurchases under the program may be made no later than December 31, 2026.
- The program is part of an opportunity from a March 2026 transaction with Gilead.
- The Gilead transaction allowed for repurchases of up to $150 million.
- The objective of the program is to deliver shareholder value.
- Purchased shares will be held as treasury shares.
- Repurchases will be carried out in the open market under approved terms.
Price Impact
More from GLPG